The population density of Levittown, PA was 5,113 in 2017.

Population Density

Population Density is computed by dividing the total population by Land Area Per Square Mile.

Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API - Notes:

1. ODN datasets and APIs are subject to change and may differ in format from the original source data in order to provide a user-friendly experience on this site.

2. To build your own apps using this data, see the ODN Dataset and API links.

3. If you use this derived data in an app, we ask that you provide a link somewhere in your applications to the Open Data Network with a citation that states: "Data for this application was provided by the Open Data Network" where "Open Data Network" links to http://opendatanetwork.com. Where an application has a region specific module, we ask that you add an additional line that states: "Data about REGIONX was provided by the Open Data Network." where REGIONX is an HREF with a name for a geographical region like "Seattle, WA" and the link points to this page URL, e.g. http://opendatanetwork.com/region/1600000US5363000/Seattle_WA

Geographic and Population Datasets Involving Levittown, PA

  • API

    Emergency Department (ED) Visits for Overdose Identified Through Syndromic Surveillance Quarter 3 2016 - Current Quarterly County Health

    data.pa.gov | Last Updated 2019-09-11T18:02:00.000Z

    View quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level. Please see Overdose Data Technical Notes for additional details: : https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

  • API

    Bronx Zip Population and Density

    bronx.lehman.cuny.edu | Last Updated 2012-10-21T14:06:17.000Z

    2010 Census Data on population, pop density, age and ethnicity per zip code

  • API

    Rate of Hospitalizations for Opioid Overdose per 100,000 Residents County Health Care Cost Containment Council (PHC4)

    data.pa.gov | Last Updated 2018-09-04T14:38:21.000Z

    County rates of hospitalizations for opioid overdose per 100,000 residents ages 15 and older. This analysis is restricted to Pennsylvania residents age 15 and older who were hospitalized in Pennsylvania general acute care hospitals.

  • API

    Educational Attainment by Age Range and Gender 2009-2016 County Annual Education

    data.pa.gov | Last Updated 2018-11-05T16:26:18.000Z

    County level educational attainment data on the adult working aged population (25-64) by age range and gender. Data is sourced from the US Census Bureau’s American Community Survey (ACS) 5-year estimates allowing for increased statistical reliability of the data for less populated areas and small population subgroups. More information here - https://www.census.gov/data/developers/data-sets/acs-5year.html

  • API

    Risky Prescribing Measures Quarter 3 2016 - Current Quarterly County & Statewide Health

    data.pa.gov | Last Updated 2019-09-11T18:37:46.000Z

    View quarterly trends in Risky Prescribing Measures, including: o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 4+ Prescribers and 4+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 3+ Prescribers and 3+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the patient’s county of residence. o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence. o Number/Rate of Individuals with > 30 Days of Overlapping Opioid/Benzodiazepine Prescriptions: Number and rate of individuals receiving overlapping opioid and benzodiazepine prescriptions for 30 days or more during a given quarter using state/county populations as denominators. This measure is based on the patients’ county of residence. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

  • API

    Buprenorphine Dispensation Data Quarter 3 2016 - Current Quarterly Statewide Health

    data.pa.gov | Last Updated 2019-09-11T17:32:05.000Z

    View quarterly trends in buprenorphine dispensation data. Please note that buprenorphine data received by the PDMP is restricted to prescriptions filled by pharmacies. The PDMP does not collect information on the reason a controlled substance is prescribed, nor does it collect data from substance abuse treatment facilities or dispensing prescribers providing buprenorphine for substance abuse treatment. Buprenorphine is sometimes prescribed off-label for pain. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

  • API

    Opioid Dispensation Data Quarter 3 2016 - Current Quarterly County Health

    data.pa.gov | Last Updated 2019-09-11T15:40:24.000Z

    View quarterly trends in opioid dispensation data for all Schedule II-V opioids. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx More information from U.S. Department of Justice https://www.deadiversion.usdoj.gov/schedules/ Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®). Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. Schedule IV Controlled Substances Substances in this schedule have a low potential for abuse relative to substances in Schedule III. Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®). Schedule V Controlled Substances Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

  • API

    Rate of Hospitalizations for Opioid Overdose per 100,000 Residents by Category Principle Diagnosis CY 2016-2017 County Health Care Cost Containment Council (PHC4)

    data.pa.gov | Last Updated 2019-01-16T16:45:37.000Z

    County rates of hospitalizations for opioid overdose categorized by principal diagnosis of heroin or opioid pain medication overdose per 100,000 residents. This analysis is restricted to Pennsylvania residents age 15 and older who were hospitalized in Pennsylvania general acute care hospitals. Disclaimer: PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers. PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

  • API

    Emergency Department (ED) Visits for Drug Overdose By Gender Identified Through Syndromic Surveillance SFY Quarter 3 2016 - Current Quarterly County Health

    data.pa.gov | Last Updated 2019-09-11T15:48:41.000Z

    Based on Emergency Department (ED) Visits view quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level. Please see Overdose Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/OverdoseDataTechnicalNotes.pdf Syndromic surveillance is the analysis of medical data to detect or anticipate disease outbreaks. According to a CDC definition, "the term 'syndromic surveillance' applies to surveillance using health-related data that precede diagnosis and signal a sufficient probability of a case or an outbreak to warrant further public health response.

  • API

    Counts and Rates of New HIV Diagnoses Among Individuals Using Injection Drugs

    data.pa.gov | Last Updated 2019-10-07T14:58:58.000Z

    This indicator includes the count and rate of new HIV diagnoses among individuals using injection drugs per 100,000 individuals estimated to have Drug Use Disorder.